STANOLOL 50 is an oral androgen, a derivative of Dihydrotestosterone (DHT). Stanozolol was originally developed to treat hereditary angioedema. As with most Androgens Stanozolol will help to create a state of anabolism and contribute to a significant increase in muscle tissue. Structurally, stanozolol is not capable of converting into estrogen therefore will not contribute to water retention which may be the case with other androgens. Also unlike most anabolic steroids, is not esterified. The drug has a large oral bioavailability, due to a C17 α-alkylation which allows the hormone to survive first pass liver metabolism when ingested.
- PRESENTATION: 50mg tablets in blister packs of 25 tablets – 2 packs per box (50 tablets)
Anabolic steroids such as Stanozolol are synthetic derivatives of testosterone.
Stanozolol has been found to increase low-density lipoproteins and decrease high-density lipoproteins. These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment.
Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficient or nonfunctional C1 esterase inhibitor (C1 INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract.
In small clinical studies, Stanozolol was effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C1 INH and C4. Stanozolol is not effective in stopping HAE attacks while they are under way. The effect of stanozolol on increasing serum levels of C1 INH and C4 may be related to an increase in protein anabolism.